Article
[SDZ PSC 833: a novel modulator of MDR].
Tumori - 1 Jan 2000
Covelli A
Abstract excerpt
SDZ PSC 833 is a novel compound able to reverse the resistance to chemotherapy of cancer cells with the multidrug resistance (MDR) phenotype by inhibiting the 170 kd P-glyco-protein (P-gp). In vitro studies show that SDZ PSC 833 directly interacts with, but is not transported by P-gp, although th...
Topics
- Animals
- Antineoplastic Agents
- Clinical Trials as Topic
- Cyclosporins
- Drug Interactions
- Drug Resistance, Multiple
- Genes, MDR
- Humans
- Neoplasms
- Phenotype